Format

Send to

Choose Destination
Tex Heart Inst J. 2010;37(4):412-20.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Author information

1
Minneapolis Heart Institute at Abbott Northwestern Hospital, USA.

Abstract

A realistic goal for cardiac cell therapy may be to attenuate left ventricular remodeling following acute myocardial infarction to prevent the development of congestive heart failure. Initial clinical trials of cell therapy have delivered cells 1 to 7 days after acute myocardial infarction. However, many patients at risk of developing congestive heart failure may not be ready for cell delivery at that time-point because of clinical instability or hospitalization at facilities without access to cell therapy. Experience with cell delivery 2 to 3 weeks after acute myocardial infarction has not to date been explored in a clinical trial. The objective of the LateTIME study is to evaluate by cardiac magnetic resonance the effect on global and regional left ventricular function, between baseline and 6 months, of a single intracoronary infusion of 150 × 106 autologous bone marrow mononuclear cells (compared with placebo) when that infusion is administered 2 to 3 weeks after moderate-to-large acute myocardial infarction. The 5 clinical sites of the Cardiovascular Cell Therapy Research Network (CCTRN) will enroll a total of 87 eligible patients in a 2:1 bone marrow mononuclear cells-to-placebo patient ratio; these 87 will have undergone successful percutaneous coronary intervention of a major coronary artery and have left ventricular ejection fractions ≤0.45 by echocardiography. When the results become available, this study should provide insight into the clinical feasibility and appropriate timing of autologous cell therapy in high-risk patients after acute myocardial infarction and percutaneous coronary intervention.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00684021.

KEYWORDS:

Apoptosis; bone marrow cells; bone marrow transplantation; cell therapy; colony-stimulating factors; free radicals; heart failure; inflammation/prevention & control; infusions, intra-arterial; magnetic resonance imaging; myocardial infarction/therapy; myocardial ischemia/therapy; myocardial reperfusion injury; myocytes, cardiac; prospective studies; regeneration; research design; stem cell transplantation; stem cells; time factors; ventricular function, left; ventricular remodeling

PMID:
20844613
PMCID:
PMC2929864
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center